NASDAQ:CNTB Connect Biopharma (CNTB) Stock Price, News & Analysis $0.87 -0.01 (-1.21%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.90 +0.04 (+4.02%) As of 10/9/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Connect Biopharma Stock (NASDAQ:CNTB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Connect Biopharma alerts:Sign Up Key Stats Today's Range$0.87▼$0.9350-Day Range$0.87▼$2.7652-Week Range$0.85▼$3.82Volume1.05 million shsAverage Volume10.74 million shsMarket Capitalization$54.78 millionP/E RatioN/ADividend YieldN/APrice Target$6.14Consensus RatingModerate Buy Company Overview Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression. Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. Connect Biopharma has also developed rademikibart, formerly known as CBP-201, an antibody targeting the interleukin-4 receptor alpha pathway for immune-mediated conditions including atopic dermatitis and other type 2 inflammatory diseases. Founded in 2012, Connect Biopharma has conducted research and clinical-development activities in the United States and China, with a focus on advancing treatments for patients with significant unmet medical needs. The company is headquartered in San Diego, California, and has historically maintained operations in China as part of its international development and research organization.AI Generated. May Contain Errors. Read More Connect Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreCNTB MarketRank™: Connect Biopharma scored higher than 65% of companies evaluated by MarketBeat, and ranked 260th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingConnect Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialConnect Biopharma has a consensus price target of $6.14, representing about 606.1% upside from its current price of $0.87.Amount of Analyst CoverageConnect Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Connect Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Connect Biopharma are expected to grow in the coming year, from ($1.09) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Connect Biopharma is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Connect Biopharma is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioConnect Biopharma has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Connect Biopharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.18% of the float of Connect Biopharma has been sold short.Short Interest Ratio / Days to CoverConnect Biopharma has a short interest ratio ("days to cover") of 0.22, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Connect Biopharma has recently increased by 26.16%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldConnect Biopharma does not currently pay a dividend.Dividend GrowthConnect Biopharma does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment-0.01 News SentimentConnect Biopharma has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Connect Biopharma this week, compared to 3 articles on an average week.Search Interest6 people have searched for CNTB on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows5 people have added Connect Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Connect Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders22.60% of the stock of Connect Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.72% of the stock of Connect Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Connect Biopharma's insider trading history. Receive CNTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTB Stock News HeadlinesConnect Biopharma (NASDAQ:CNTB) Earns "Buy" Rating from HC Wainwright2 hours ago | americanbankingnews.comHC Wainwright Issues Pessimistic Outlook for CNTB EarningsOctober 6, 2026 | americanbankingnews.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider. | Weiss Ratings (Ad)Financial Contrast: Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX)October 5, 2026 | americanbankingnews.comConnect Biopharma (NASDAQ:CNTB) Stock Rating Reaffirmed as "Buy" by HC WainwrightOctober 4, 2026 | americanbankingnews.comConnect Biopharma Holdings consensus price target decreased by 18.97% to $5.99October 2, 2026 | msn.comLake Street Sticks to Its Buy Rating for Connect Biopharma Holdings (CNTB)October 2, 2026 | theglobeandmail.comBTIG Research Has Lowered Expectations for Connect Biopharma (NASDAQ:CNTB) Stock PriceOctober 2, 2026 | americanbankingnews.comSee More Headlines CNTB Stock Analysis - Frequently Asked Questions How have CNTB shares performed this year? Connect Biopharma's stock was trading at $2.82 at the beginning of 2026. Since then, CNTB stock has decreased by 69.1% and is now trading at $0.87. How were Connect Biopharma's earnings last quarter? Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) released its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.04. The firm earned $2.75 million during the quarter, compared to analyst estimates of $0.74 million. When did Connect Biopharma IPO? Connect Biopharma (CNTB) raised $180 million in an initial public offering on Friday, March 19th 2021. The company issued 11,250,000 shares at $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO. How do I buy shares of Connect Biopharma? Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Connect Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Connect Biopharma investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Builders FirstSource (BLDR) and Company Calendar Last Earnings8/12/2026Today10/10/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 2 days ago, CNTB's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CNTB CIK1835268 Webwww.connectbiopharma.com Phone(858) 727-1040Fax+1 8586147007Employees64Year Founded2012Price Target and Rating Average Price Target for Connect Biopharma$6.14 High Price Target$9.00 Low Price Target$4.00 Potential Upside/Downside+606.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.48 million Net MarginsN/A Pretax Margin-2,329.67% Return on Equity-165.41% Return on Assets-121.58% Debt Debt-to-Equity Ratio0.01 Current Ratio2.37 Quick Ratio2.37 Sales & Book Value Annual Sales$60 thousand Price / Sales913.07 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book1.16Miscellaneous Outstanding Shares62,970,000Free Float48,742,000Market Cap$54.78 million OptionableOptionable Beta-0.16 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CNTB) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredMy next big call (under $1)On the first day of October, one of the biggest banks in the world changed its mind about Bitcoin. Citigroup r...Crypto 101 Media | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTB Stock Alerts